Medindia

X

Potential New Heart Attack Biomarker Identified

by VR Sreeraman on  December 13, 2009 at 2:04 PM Heart Disease News   - G J E 4
 Potential New Heart Attack Biomarker Identified
Researchers in the UK have identified a potential new diagnostic biomarker for heart attacks.
Advertisement

Presently, one of the gold-standards for diagnosis of heart attacks, or acute myocardial infarctions, is scanning for the presence of the proteins troponin I and troponin T, as they are produced specifically in the heart and are almost completely absent in the blood in healthy individuals.

Advertisement
However, even troponins are not ideal markers, since they are released somewhat slowly following a heart attack and remain in the blood for up to 10 days afterwards, hindering the diagnosis of any secondary heart attacks.

In search for better biomarkers, researchers at King's College London performed a proteomic analysis of all the proteins released by mouse hearts following induced heart attacks.

They identified 320 proteins not released by normal hearts, including all the currently employed biomarkers.

Only a handful of these proteins were specific to the heart, but among those, one very promising lead was cardiac myosin-binding protein C cMyBP-C; within 5 minutes following a heart attack it became nearly 20 fold more abundant than before, one of the highest increases of all 320 identified proteins.

In fact, cMyBP-C was abundant following even minor heart attacks, suggesting it could be very useful in such instances.

The researchers are now continuing their investigation and examining the time course of cMyBP-C release following heart attacks and its persistence in the blood of mice, to further determine this protein's potential value.

The study appears in this month's Molecular and Cellular Proteomics.

Source: ANI
SRM
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
The ischemic biomarker Heart-type Fatty Acid Binding Protein [H-FABP] can substantially improve the detection of high risk patients when Troponin-negative, even when a high sensitivity assay is used, a new publication has shown. In June’s edition of JACC, Professor Alistair Hall and colleagues from the University of Leeds, UK, prospectively studied a cohort of 1080 consecutive patients admitted to hospital with suspected ACS and compared the H-FABP assay (Randox Laboratories) with the high sensitivity Ultra-TnI assay (Siemens Healthcare Diagnostics).
Randox Monday, November 15, 2010

You May Also Like

Advertisement
View All